Prospective Screening for Patient-Specific Genotypes and Phenotypes That Influence Drug Dosing and Trial Selection in Cancer Patients

Launched by NATIONAL CANCER INSTITUTE (NCI) · Mar 8, 2016

Keywords

ClinConnect Summary

Background:

Genetic sequence of drug-metabolizing enzymes, transporters/receptors, transcription factors, drug targets, and patient baseline characteristics often affect an individual s response to drug therapy. Expression of such genes is also influenced by the epigenome and regulation by a variety of other factors: RNA expression, protein expression, disease state, comorbidities, concomitant therapies, etc. Therefore, inter-patient variability in drug pharmacokinetics and outcome is often a function of these factors.

Inter-individual differences in efficacy and toxicity of cancer chemot...

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• • Any patient who is being evaluated for and/or treated on an IRB-approved protocol at the National Cancer Institute.
• • Age \>18 years.
• • Ability of subject to understand and the willingness to sign a written informed consent document.
• EXCLUSION CRITERIA:
• • - A patient will be excluded if there is an insufficient quality or quantity of sample available to perform the assay and no further sample can be drawn in order to re-assess the status of a genetic or biomarker.